Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

November 18, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Seasonal influenza A virus (IAV) vaccines with High-Affinity Antibodies

The connection between Aerosols and Tropical Thunderstorms established!

Mesenchymal Stem Cells Used in SARS-CoV-2 Patients Show Promising Results

Seasonal influenza A virus (IAV) vaccines with High-Affinity Antibodies
  • BiotechToday
  • World

Seasonal influenza A virus (IAV) vaccines with High-Affinity Antibodies

bioxone January 11, 2021January 11, 2021

Thota Kanishka Rao, Amity University Kolkata

Improving the age of comprehensively receptive antibodies against influenza A virus (IAV) is a pertinent objective toward building up a global IAV immunization. While antibodies that bind conserved IAV epitopes have been recognized in people, antibodies specific for the variable epitopes are substantially more predominant than antibodies perceiving conserved epitopes. 

It is essential to characterize the elements that limit the generation of broadly responsive IAV antibodies to build up a powerful general IAV vaccine. The prevalent hypothesis was that competition inside germinal centers favors the synthesis of high-affinity antibodies specific for the variable locale of the virus, and limits antibodies explicit for conserved IAV epitopes.

Researchers in this experiment demonstrated that reducing the germinal centre formation and eliminating competition with high-affinity antibodies was not adequate to increase extensively reactive IAV antibodies or improve protection against particular IAV subtypes. This information disprove the prevailing hypothesis that extensively responsive IAV antibodies are uncommon because of competition inside germinal centres, and uncover the basic need to additionally research factors that limit comprehensively receptive IAV antibodies.

 Furthermore, the information reveals that IAV-explicit IgM antibodies persist in mice without germinal centers, featuring the protective capacity of germinal center-independent IgM antibodies, which are not normally considered when testing corresponds of protection, and offer a substitute objective for conveying a widespread IAV immunization.

It is assessed that 250,000 to 650,000 individuals globally die in a calendar year due to seasonal influenza A virus (IAV) infections. 

Current antibodies give little assurance against newly emerging strains. In this way, significant effort is centered around improving the generation of broadly receptive IAV antibodies to build up a general IAV vaccine. Understanding the elements that constrain improvement of antibodies specific for conserved regions of IAV is basic for building up a compelling all universal IAV vaccine, which might evade a calamitous pandemic. These discoveries are huge as they feature the significance of researching different instruments that add to the lack of broadly responsive IAV antibodies.

Also read:The connection between Aerosols and Tropical Thunderstorms established!

Source: Broadly Reactive Influenza Antibodies Are Not Limited by Germinal Center Competition with High-Affinity Antibodies Rachael Keating, Jenny L. Johnson, David C. Brice, Jocelyn G. Labombarde, Alexander L. Dent, Maureen A. McGargill mBio Nov 2020, 11 (6) e01859-20; DOI:http://10.1128/mBio.01859-20

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Antibody répertoire humoral immunity IAV immunisation influenza influenza A virus influenza vaccines

One thought on “Seasonal influenza A virus (IAV) vaccines with High-Affinity Antibodies”

  1. Pingback: Mesenchymal Stem Cells Used in SARS-CoV-2 Patients Show Promising Results - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Mesenchymal Stem Cells Used in SARS-CoV-2 Patients Show Promising Results

bioxone January 11, 2021

Sumedha Guha, Techno India University A ground-breaking randomized trial at the University Of Miami Miller School Of Medicine has given us a new treatment for SARS-CoV-2 patients. In the trial that was led by Dr. Camillo Ricordi, M.D., mesenchymal stem cells of the umbilical cord were infused into the body of patients severely affected by […]

Stem Cells

Related Post

  • BiotechToday
  • World

Genomic analysis of the cells in Human Breast milk

bioxone July 3, 2021July 2, 2021

Saakshi Bangera, DY Patil School of Biotechnology and Bioinformatics Sarah Nyquist is a PhD candidate in MIT’s computational and systems biology department who attempted to use machine learning to understand the genomic composition of breast milk. Along with her co-advisor professors – Alex Shalek and Bonnie Berger, she aimed at using computational tools to study […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

A Global Map of Urban Microbiomes and antimicrobial resistance.

bioxone June 1, 2021June 1, 2021

Sagnik Nag, Amity University, Kolkata Microbes within the built environment are implicated as a feasible source of contagion and certain syndromes, like allergies, are related to increasing urbanization. It’s now evident that cities, generally, have a notion on human health, though the mechanisms of this impact are broadly variable and sometimes little understood. Indeed, our […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

High risk of COVID-19 in organ transplant patients

BioTech Today July 29, 2021July 29, 2021

Soumya Shraddhya Paul, Amity University, Noida The extent to which Covid vaccinations can protect people who have organ transplants is yet unknown. Transplantation doctors have long feared that the Covid vaccinations aren’t providing enough protection to patients undergoing transplants. Few studies have suggested that even after being completely vaccinated with mRNA vaccines, which are believed […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy